Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > I will
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(40)
•••
Comment by Belgiumboyon Apr 21, 2020 5:44am
119 Views
Post# 30932904

RE:RE:RE:RE:I will

RE:RE:RE:RE:I will
indaknownewfie wrote: Well my reaction would only be my opinion. Could Kalytera be working on a conditional FDA approval behind the scenes? Absolutely because the results were so stellar. Do I think something is brewing behind the scenes?  I've long held the belief that there is more happening behind the scenes. Perhaps that is conjecture on my part. I wouldn't want anyone to make an investment solely on what they read here on stockhouse BB. Suffice it it to say that I'm content with my own personal decision enough to not sell any of my shares or warrants which constitutes a sizeable position for my own portfolio. Would I like more shareholder engagement? well the answer to that is yes sir,  but i believe we will be in a position in the near future to have a dedicated person in that regard. Just my humble opinion and I wish everyone luck. 


Thanks for your reaction Indaknow
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities